Anika Therapeutics Reports Q3 Revenue Growth and Raises 2026 Guidance
Third-quarter 2026 revenue rose 10% year over year to $30.6 million. Anika raised the lower end of its full-year revenue guidance and increased adjusted EBITDA guidance.
Anika Therapeutics reported third-quarter 2026 revenue of $30.6 million, a 10% increase compared to the prior-year period, driven by growth in its Commercial and OEM channels. The company raised the lower end of its full-year 2026 total revenue guidance and increased its adjusted EBITDA guidance. Operational highlights included a new 10-year distribution partnership for Hyvisc with Boehringer Ingelheim and the U.S. reintroduction of the Hyalomatrix wound product.
Additionally, Anika completed enrollment for its Cingal bioequivalence study and expects to submit an NDA before the end of 2027. The company also noted progress in manufacturing, including FDA approval for new aseptic processes.